Law C H, Tandan V R
Department of Surgery, St. Joseph's Hospital, McMaster University, Hamilton, Ont.
Can J Surg. 1999 Jun;42(3):211-4.
Tamoxifen has become one of the most widely used drugs in the treatment of breast cancer, and concerns about its long-term safety and efficacy are being raised. Investigations in rats have suggested an association between the administration of tamoxifen and the development of hepatocellular carcinoma. However, no studies to date have demonstrated an increased incidence of hepatocellular carcinoma in women treated with tamoxifen. In the case reported, a 56-year-old woman presented with hepatocellular tumours after 6 years of tamoxifen therapy for breast cancer. The patient had no other risk factors for the development of hepatocellular carcinoma. She underwent successful resection of the lesions, and subsequent pathological studies confirmed hepatocellular carcinoma with a trabecular growth pattern similar to the histologic pattern seen in tamoxifen-induced hepatocellular carcinoma occurring in rat models.
他莫昔芬已成为治疗乳腺癌最广泛使用的药物之一，人们对其长期安全性和疗效的担忧也在增加。对大鼠的研究表明，服用他莫昔芬与肝细胞癌的发生有关。然而，迄今为止尚无研究表明接受他莫昔芬治疗的女性肝细胞癌发病率增加。在本报告的病例中，一名56岁女性在接受他莫昔芬治疗乳腺癌6年后出现肝细胞肿瘤。该患者没有其他肝细胞癌发生的风险因素。她成功切除了病变，随后的病理研究证实为肝细胞癌，其小梁生长模式与大鼠模型中他莫昔芬诱导的肝细胞癌的组织学模式相似。
